Primary squamous cell carcinoma of the breast: sensitivity to cisplatinum-based chemotherapy. J Surg Oncol 1995 Jul;59(3):199-203
Date
07/01/1995Pubmed ID
7609529DOI
10.1002/jso.2930590313Scopus ID
2-s2.0-0029041937 (requires institutional sign-in at Scopus site) 69 CitationsAbstract
Primary squamous cell carcinoma (SCC) of the breast is a rare malignancy whose optimal treatment and prognosis are unknown. A patient with SCC whose tumor responded dramatically to chemotherapy as part of multimodal treatment is presented. A 61-year-old woman had a palpable 5.5-cm tender left breast mass with overlying skin edema and erythema and irregular margins by mammography. Fine needle aspiration revealed malignant squamous cells with keratinization; incisional biopsy confirmed SCC. Extensive evaluation for an extramammary primary site of disease was negative. Neoadjuvant cisplatinum and 5-fluorouracil (5-FU) led to tumor shrinkage and complete resolution of pain and erythema. Modified radical mastectomy with post-operative chest wall radiation were performed. Neither residual invasive carcinoma nor metastatic nodal disease was found, though intraductal carcinoma with marked squamous features was identified. The patient remains disease-free 2.5 years after diagnosis. Cisplatinum-based chemotherapy should be considered in the treatment regimen of this disease.
Author List
Dejager D, Redlich PN, Dayer AM, Davis HL, Komorowski RAAuthor
Philip N. Redlich MD, PhD Professor in the Surgery department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Antineoplastic Combined Chemotherapy ProtocolsBiopsy, Needle
Breast
Breast Neoplasms
Carcinoma, Squamous Cell
Chemotherapy, Adjuvant
Cisplatin
Combined Modality Therapy
Disease-Free Survival
Female
Humans
Mastectomy, Modified Radical
Middle Aged
